Clinical trials
HIV-1 clinical trials
Below are recruiting hiv-1 clinical trials, each written for real people, not researchers. We’re tracking 79 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07645287RecruitingPhase 2
New HIV Combination Therapy for People on Biktarvy
This study tests a new HIV medication (GS-3242) combined with lenacapavir against your current Biktarvy regimen. Both are all-oral treatments for people whose HIV is well-controlled.
Beverly Hills, CaliforniaAges 18 years+ - NCT06071767RecruitingPhase 1/Phase 2
Immune therapy trial for early-treated HIV
This study tests whether a combination of three immune therapies can help control HIV without daily medication. You may qualify if you started HIV treatment very early and have had a suppressed viral load for at least a year.
San Diego, CaliforniaAges 18 years+ - NCT06517693RecruitingPhase 1
HIV antibody safety study for newborns at risk
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
Los Angeles, CaliforniaAges Up to 3 days - NCT07370649Recruiting
Long-acting HIV injectable study for subtype A6
This study looks back at medical records of people with HIV-1 who have received a long-acting injectable treatment called cabotegravir plus rilpivirine. It aims to see how well this treatment works for people with a specific HIV subtype (A6).
PragueAges 18 years+ - NCT07708727RecruitingPhase 2/Phase 3
Injectable HIV treatment vs daily pill for new patients
This trial tests a new injectable HIV treatment (GS-3242 plus lenacapavir) compared to the daily pill Biktarvy for people just starting HIV therapy. If you qualify, you would receive shots every few weeks instead of taking a daily pill.
Ft. Pierce, FloridaAges 18 years+ - NCT06203132RecruitingPhase 3
Doravirine vs Dolutegravir for first-time HIV treatment
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
Nova Iguaçu, Rio de JaneiroAges 18 years+ - NCT06640192RecruitingPhase 2
High-dose HIV drugs to clear hidden virus
This study tests whether giving very high doses of your current HIV meds can flush out hidden HIV that stays in the body even when the virus is undetectable. It might help find a way to reduce or eliminate the reservoir of latent HIV.
Madrid, MadridAges 18–60 - NCT05215704Recruiting
Lab study of dormant HIV using samples from you
This trial collects blood samples from people living with HIV to study dormant (inactive) HIV cells in the lab. The goal is to better understand how to target these hidden cells as part of an eventual cure.
RotterdamAges 18 years+ - NCT06602622RecruitingPhase 4
Weight change study for people with HIV switching to DOR/3TC/TDF
This study tests whether switching your HIV medication to a combination called DOR/3TC/TDF can help with weight changes that started after taking another type of HIV drug (integrase inhibitor). It is for people who have gained weight unintentionally and want to see if a different medication helps manage it.
Mexico City, AzcapotzalcoAges 18–80 - NCT06631365RecruitingPhase 2
PrEP on demand: a pilot study for men who have sex with men
This study tests a '2-1-1' on-demand PrEP strategy for cisgender men who have sex with men. It aims to see if taking PrEP only around the time of sex is safe and effective. If you are interested in starting or currently taking PrEP this way, you may be eligible.
San Francisco, CaliforniaAges 18 years+ - NCT07683000RecruitingPhase 3
Study of three HIV drugs for adults with controlled HIV
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
Berkeley, MichiganAges 18 years+ - NCT07476339RecruitingPhase 4
Returning to HIV Care with Biktarvy
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
Clearwater, FloridaAges 18 years+ - NCT05143307Enrolling by invitationPhase 1
Follow-up study for adults who received EBT-101 for HIV
This study checks how adults are doing long-term after receiving an HIV treatment called EBT-101 in an earlier study. It helps researchers understand safety and longer-term effects over time.
San Francisco, CaliforniaAges 18 years+ - NCT06646562RecruitingPhase 4
Long-acting injectable HIV meds for adults 60 and older
This study tests whether two long-acting injectable HIV medications (cabotegravir and rilpivirine) can keep the virus under control in people aged 60 and older. It aims to offer a convenient alternative to daily pills for older adults with HIV.
Elche, AlicanteAges 60 years+ - NCT06880380RecruitingPhase 1
CAR-T cell therapy for functional HIV cure
This trial tests whether CAR-T cells can help control HIV without daily antivirals. It is for people with well-controlled HIV who want to explore a potential functional cure.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT05584397Enrolling by invitation
Compare immune activity and HIV hidden reservoir on two treatments
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
Seattle, WashingtonAges 18–65 - NCT06749054RecruitingPhase 2
Long-acting HIV treatment for teens and children with drug resistance
This trial tests a long-acting injection called lenacapavir for children and teens with HIV who have tried other treatments and still have detectable virus. It may be an option if current medicines aren't working well enough.
Atlanta, GeorgiaAges Up to 17 years - NCT04553081RecruitingPhase 4
Switching HIV treatment: 2-drug versus 3-drug plan
This trial compares two different HIV treatment plans: keeping you on a 2-drug regimen versus switching to a 3-drug regimen. It’s designed for people whose HIV is well controlled and looks at whether the switch is safe and effective.
GhentAges 18 years+ - NCT05660980RecruitingPhase 1/Phase 2
Oral and monthly shots for HIV control in children
This trial studies whether a child can safely move from HIV medicine taken by mouth to long-acting monthly injections. It looks at keeping HIV levels suppressed (very low) and monitoring side effects and safety over time.
Atlanta, GeorgiaAges 2–11 - NCT04098315Recruiting
HIV drug-resistance patient registry study for people 14+
This study is a registry (a way to collect and organize information) for people living with HIV who have drug-resistant virus. It may help researchers better understand how resistant HIV behaves and how to manage treatment over time.
Milan, MIAges 14 years+ - NCT07266831RecruitingPhase 2/Phase 3
Study of islatravir and ulonivirine for new HIV patients
This trial tests two new HIV medications, islatravir and ulonivirine, in people who have never taken HIV treatment before. It aims to see if this combination can safely control the virus.
Los Angeles, CaliforniaAges 18 years+ - NCT07390955RecruitingPhase 1
Safety study of three anti-HIV antibodies in healthy adults
This study is testing three experimental antibodies (ePGT121v1-LS, PGDM1400LS, and VRC07-523LS) that may help prevent HIV. It’s looking at their safety and how long they stay in the body. Healthy volunteers without HIV can join.
Birmingham, AlabamaAges 18–55 - NCT07275606RecruitingPhase 1/Phase 2
Testing HIV prevention medicine cabotegravir in newborns
This study tests a long-acting injectable HIV prevention medicine called cabotegravir in newborn babies who were exposed to HIV. The goal is to see if it can help protect them from getting HIV.
Parow ValleyAges Up to 1 week - NCT06900829Recruiting
HIV testing program for European hospitals
This trial helps hospitals find undiagnosed HIV by improving testing and care. It supports healthcare teams to identify HIV in people with certain conditions and ensures those diagnosed get connected to treatment.
GhentAges 18 years+
Hear when a new HIV-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv-1?
- Yes. Clin2 currently lists 79 recruiting hiv-1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv-1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv-1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.